“Update on Human Papillomavirus Infection in HIV-Infected Patients”
December 15, 2016
12:00 PM (EST) - 1:00 PM (EST)
JMB Class of 1962 Auditorium
Timothy J. Wilkin, MD, MPH
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York
Target Audience
This program has been designed for physicians, fellows, residents, medical students, physician assistants, pharmacists, medical assistants, professional nurses, advanced practice nurses in the medical specialties of dermatology, family medicine, internal medicine, infectious diseases, obstetrics and gynecology, pediatrics, psychiatry and neurology.
Series Educational Objectives
After completing this activity, participants should be able to:
- Apply in clinical practice approaches for preventing HIV infection and getting newly diagnosed patients into care
- Individualize ARV therapy for the treatment-naïve and treatment-experienced patients
- Manage the aging patient with HIV infection, including issues associated with cardiovascular and bone disease
Session Educational Objectives
After completing this activity, participants should be able to:
- Identify the rationale and current approach to anal cancer screening
- Describe current treatment approaches for anal cancer precursors
- Review current indications for HPV vaccination among HIV-infected people
Accreditation
The activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Perelman School of Medicine at the University of Pennsylvania and ViralEd, Inc. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Physicians: The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgement of Commercial Support* Merck, Gilead. Bristol-Myers Squibb, and VIIV Healthcare
For more information, please contact
Rick Gordon
847-951-5318
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania and the Hospital of the University of Pennsylvania, Department of Nursing Education, Innovation and Professional Developmentfor individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose we consider relationships of the person involved to include financial relationships of a spouse or partner.
The intent of this policy is to ensure that Penn CME/CNE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic, CHCP, FACEHP, Director of CME,Zalman Agus, MD,Senior peer reviewerand Patricia A. Smith, DNP, RN-BC,Nursing professional development specialist of the HUP Department of Nursing Innovation and Development have disclosed that they have norelevant financial relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity:
Planning Committee Member Name
Brian, Boyle, MD / Rick Gordon / Oliver FultzThe following individuals have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity.
Planning Committee Member NameName of Commercial InterestRelationship
Ian Frank, MDGileadAdvisory Board
ViiV, GlaxoSmithKline & Bavarian NordicResearch
PRESENTER NAMEName of Commercial InterestRelationship
Timothy J. Wilkin, MD, MPHGlaxoSmithKlineConsultant, Research
Gilead, Bristol-Myers SquibbResearch
Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected
Disclosure of Unapproved Uses of Products
Presenter nameProductInvestigational and/or Off-label Use
Timothy J. Wilkin, MD, MPH4 valent and 9 valent HPV vaccinePrevention of HPV-associated
oropharyngeal cancer